Global and United States Infectious Diseases Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Infectious Diseases Market Size Growth Rate by Type: 2020 VS 2026
  • 1.2.2 Antibacterial drugs
  • 1.2.3 Antiviral drugs
  • 1.2.4 Antifungal drugs
  • 1.2.5 Antiparasitic drugs
• 1.3 Market by Application
  • 1.3.1 Global Infectious Diseases Market Share by Application: 2020 VS 2026
  • 1.3.2 Acquired Immune Deficiency Syndrome
  • 1.3.3 Hepatitis B
  • 1.3.4 Hepatitis C
  • 1.3.5 Human Papillomavirus
  • 1.3.6 Hospital acquired Methicillin-resistant Staphylococcus aureus infection
  • 1.3.7 Chlamydia trachomatis and Neisseria Gonorrhea
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Infectious Diseases Market Perspective (2015-2026)
• 2.2 Global Infectious Diseases Growth Trends by Regions
  • 2.2.1 Infectious Diseases Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Infectious Diseases Historic Market Share by Regions (2015-2020)
  • 2.2.3 Infectious Diseases Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Infectious Diseases Players by Market Size
  • 3.1.1 Global Top Infectious Diseases Players by Revenue (2015-2020)
  • 3.1.2 Global Infectious Diseases Revenue Market Share by Players (2015-2020)
• 3.2 Global Infectious Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Infectious Diseases Revenue
• 3.4 Global Infectious Diseases Market Concentration Ratio
  • 3.4.1 Global Infectious Diseases Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Infectious Diseases Revenue in 2019
• 3.5 Key Players Infectious Diseases Area Served
• 3.6 Key Players Infectious Diseases Product Solution and Service
• 3.7 Date of Enter into Infectious Diseases Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Infectious Diseases Breakdown Data by Type (2015-2026)

• 4.1 Global Infectious Diseases Historic Market Size by Type (2015-2020)
• 4.2 Global Infectious Diseases Forecasted Market Size by Type (2021-2026)

5 Infectious Diseases Breakdown Data by Application (2015-2026)

• 5.1 Global Infectious Diseases Historic Market Size by Application (2015-2020)
• 5.2 Global Infectious Diseases Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Infectious Diseases Market Size (2015-2026)
• 6.2 North America Infectious Diseases Market Size by Type (2015-2020)
• 6.3 North America Infectious Diseases Market Size by Application (2015-2020)
• 6.4 North America Infectious Diseases Market Size by Country (2015-2020)
  • 6.4.1 United States
  • 6.4.2 Canada

7 Europe

• 7.1 Europe Infectious Diseases Market Size (2015-2026)
• 7.2 Europe Infectious Diseases Market Size by Type (2015-2020)
• 7.3 Europe Infectious Diseases Market Size by Application (2015-2020)
• 7.4 Europe Infectious Diseases Market Size by Country (2015-2020)
  • 7.4.1 Germany
  • 7.4.2 France
  • 7.4.3 U.K.
  • 7.4.4 Italy
  • 7.4.5 Russia
  • 7.4.6 Nordic
  • 7.4.7 Rest of Europe

8 China

• 8.1 China Infectious Diseases Market Size (2015-2026)
• 8.2 China Infectious Diseases Market Size by Type (2015-2020)
• 8.3 China Infectious Diseases Market Size by Application (2015-2020)
• 8.4 China Infectious Diseases Market Size by Region (2015-2020)
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 South Korea
  • 8.4.4 Southeast Asia
  • 8.4.5 India
  • 8.4.6 Australia
  • 8.4.7 Rest of Asia-Pacific

9 Japan

• 9.1 Japan Infectious Diseases Market Size (2015-2026)
• 9.2 Japan Infectious Diseases Market Size by Type (2015-2020)
• 9.3 Japan Infectious Diseases Market Size by Application (2015-2020)
• 9.4 Japan Infectious Diseases Market Size by Country (2015-2020)
  • 9.4.1 Mexico
  • 9.4.2 Brazil

10 Southeast Asia

• 10.1 Southeast Asia Infectious Diseases Market Size (2015-2026)
• 10.2 Southeast Asia Infectious Diseases Market Size by Type (2015-2020)
• 10.3 Southeast Asia Infectious Diseases Market Size by Application (2015-2020)
• 10.4 Southeast Asia Infectious Diseases Market Size by Country (2015-2020)
  • 10.4.1 Turkey
  • 10.4.2 Saudi Arabia
  • 10.4.3 UAE
  • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

• 11.1 F. Hoffmann-La Roche
  • 11.1.1 F. Hoffmann-La Roche Company Details
  • 11.1.2 F. Hoffmann-La Roche Business Overview
  • 11.1.3 F. Hoffmann-La Roche Infectious Diseases Introduction
  • 11.1.4 F. Hoffmann-La Roche Revenue in Infectious Diseases Business (2015-2020))
  • 11.1.5 F. Hoffmann-La Roche Recent Development
• 11.2 Gilead Sciences
  • 11.2.1 Gilead Sciences Company Details
  • 11.2.2 Gilead Sciences Business Overview
  • 11.2.3 Gilead Sciences Infectious Diseases Introduction
  • 11.2.4 Gilead Sciences Revenue in Infectious Diseases Business (2015-2020)
  • 11.2.5 Gilead Sciences Recent Development
• 11.3 GlaxoSmithKline
  • 11.3.1 GlaxoSmithKline Company Details
  • 11.3.2 GlaxoSmithKline Business Overview
  • 11.3.3 GlaxoSmithKline Infectious Diseases Introduction
  • 11.3.4 GlaxoSmithKline Revenue in Infectious Diseases Business (2015-2020)
  • 11.3.5 GlaxoSmithKline Recent Development
• 11.4 Johnson & Johnson
  • 11.4.1 Johnson & Johnson Company Details
  • 11.4.2 Johnson & Johnson Business Overview
  • 11.4.3 Johnson & Johnson Infectious Diseases Introduction
  • 11.4.4 Johnson & Johnson Revenue in Infectious Diseases Business (2015-2020)
  • 11.4.5 Johnson & Johnson Recent Development
• 11.5 Merck
  • 11.5.1 Merck Company Details
  • 11.5.2 Merck Business Overview
  • 11.5.3 Merck Infectious Diseases Introduction
  • 11.5.4 Merck Revenue in Infectious Diseases Business (2015-2020)
  • 11.5.5 Merck Recent Development
• 11.6 Pfizer
  • 11.6.1 Pfizer Company Details
  • 11.6.2 Pfizer Business Overview
  • 11.6.3 Pfizer Infectious Diseases Introduction
  • 11.6.4 Pfizer Revenue in Infectious Diseases Business (2015-2020)
  • 11.6.5 Pfizer Recent Development
• 11.7 AbbVie
  • 11.7.1 AbbVie Company Details
  • 11.7.2 AbbVie Business Overview
  • 11.7.3 AbbVie Infectious Diseases Introduction
  • 11.7.4 AbbVie Revenue in Infectious Diseases Business (2015-2020)
  • 11.7.5 AbbVie Recent Development
• 11.8 Astellas Pharma
  • 11.8.1 Astellas Pharma Company Details
  • 11.8.2 Astellas Pharma Business Overview
  • 11.8.3 Astellas Pharma Infectious Diseases Introduction
  • 11.8.4 Astellas Pharma Revenue in Infectious Diseases Business (2015-2020)
  • 11.8.5 Astellas Pharma Recent Development
• 11.9 AstraZeneca
  • 11.9.1 AstraZeneca Company Details
  • 11.9.2 AstraZeneca Business Overview
  • 11.9.3 AstraZeneca Infectious Diseases Introduction
  • 11.9.4 AstraZeneca Revenue in Infectious Diseases Business (2015-2020)
  • 11.9.5 AstraZeneca Recent Development
• 11.10 Bayer
  • 11.10.1 Bayer Company Details
  • 11.10.2 Bayer Business Overview
  • 11.10.3 Bayer Infectious Diseases Introduction
  • 11.10.4 Bayer Revenue in Infectious Diseases Business (2015-2020)
  • 11.10.5 Bayer Recent Development
• 11.11 Bristol-Myers Squibb
  • 10.11.1 Bristol-Myers Squibb Company Details
  • 10.11.2 Bristol-Myers Squibb Business Overview
  • 10.11.3 Bristol-Myers Squibb Infectious Diseases Introduction
  • 10.11.4 Bristol-Myers Squibb Revenue in Infectious Diseases Business (2015-2020)
  • 10.11.5 Bristol-Myers Squibb Recent Development
• 11.12 Chimerix Pharmaceuticals
  • 10.12.1 Chimerix Pharmaceuticals Company Details
  • 10.12.2 Chimerix Pharmaceuticals Business Overview
  • 10.12.3 Chimerix Pharmaceuticals Infectious Diseases Introduction
  • 10.12.4 Chimerix Pharmaceuticals Revenue in Infectious Diseases Business (2015-2020)
  • 10.12.5 Chimerix Pharmaceuticals Recent Development
• 11.13 Cubist
  • 10.13.1 Cubist Company Details
  • 10.13.2 Cubist Business Overview
  • 10.13.3 Cubist Infectious Diseases Introduction
  • 10.13.4 Cubist Revenue in Infectious Diseases Business (2015-2020)
  • 10.13.5 Cubist Recent Development
• 11.14 Eli Lilly
  • 10.14.1 Eli Lilly Company Details
  • 10.14.2 Eli Lilly Business Overview
  • 10.14.3 Eli Lilly Infectious Diseases Introduction
  • 10.14.4 Eli Lilly Revenue in Infectious Diseases Business (2015-2020)
  • 10.14.5 Eli Lilly Recent Development
• 11.15 Isis Pharmaceuticals
  • 10.15.1 Isis Pharmaceuticals Company Details
  • 10.15.2 Isis Pharmaceuticals Business Overview
  • 10.15.3 Isis Pharmaceuticals Infectious Diseases Introduction
  • 10.15.4 Isis Pharmaceuticals Revenue in Infectious Diseases Business (2015-2020)
  • 10.15.5 Isis Pharmaceuticals Recent Development
• 11.16 Mitsubishi Tanabe Pharma
  • 10.16.1 Mitsubishi Tanabe Pharma Company Details
  • 10.16.2 Mitsubishi Tanabe Pharma Business Overview
  • 10.16.3 Mitsubishi Tanabe Pharma Infectious Diseases Introduction
  • 10.16.4 Mitsubishi Tanabe Pharma Revenue in Infectious Diseases Business (2015-2020)
  • 10.16.5 Mitsubishi Tanabe Pharma Recent Development
• 11.17 Novartis
  • 10.17.1 Novartis Company Details
  • 10.17.2 Novartis Business Overview
  • 10.17.3 Novartis Infectious Diseases Introduction
  • 10.17.4 Novartis Revenue in Infectious Diseases Business (2015-2020)
  • 10.17.5 Novartis Recent Development
• 11.18 Sanofi
  • 10.18.1 Sanofi Company Details
  • 10.18.2 Sanofi Business Overview
  • 10.18.3 Sanofi Infectious Diseases Introduction
  • 10.18.4 Sanofi Revenue in Infectious Diseases Business (2015-2020)
  • 10.18.5 Sanofi Recent Development
• 11.19 Vertex
  • 10.19.1 Vertex Company Details
  • 10.19.2 Vertex Business Overview
  • 10.19.3 Vertex Infectious Diseases Introduction
  • 10.19.4 Vertex Revenue in Infectious Diseases Business (2015-2020)
  • 10.19.5 Vertex Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer